Our analysis of TMAs from 13 different cancer indications revealed that all were comprised of over 60% of patients with high CD36, with the exception of Hepatocellular carcinoma (HCC), which was comprised of 57% of patients with high CD36 expression (Fig. 2a and Table 5). The gene discussed is CD36; the disease is cancer.